Work

A phase II study of vibecotamab, a CD3-CD123 bispecific T-cell engaging antibody, for MRD-positive AML and MDS after hypomethylating agent failure.

Year: 2023

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2023.41.16_suppl.tps7076

Authors: Nicholas James Short, Pavan Bachireddy, Xuelin Huang, Hyunsoo Hwang, Xiaohong Leng, Jaehyun Lee, Danielle Nguyen, Guillermo Garcia-Manero, Courtney Denton Dinardo, Gautam Borthakur, Tapan M. Kadia, Naval Guastad Daver, Ghayas C. Issa, Abhishek Maiti, Farhad Ravandi

Institution: The University of Texas MD Anderson Cancer Center

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: University of Texas MD Anderson Cancer Center

OpenAlex ID: W4379332799

Cites:

Cited by: 8

Related to: 10